RadNet has successfully finalized its acquisition of iCAD (ICAD, Financial), integrating iCAD's commercial, technological, and regulatory expertise into its DeepHealth division. This merger aims to enhance DeepHealth's capabilities in addressing clinical and operational challenges related to medical screening and diagnostics through advanced AI and imaging technologies. The move is expected to significantly improve the accuracy in detecting breast cancer early and facilitate the management of extensive screening programs, thereby advancing the future of breast cancer care.
This strategic integration is poised to expedite growth and innovation in delivering transformative, AI-driven health solutions that address population health needs. The synergy between the two companies is set to offer enhanced tools and solutions for healthcare professionals, ultimately driving progress in the field of diagnostic imaging.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for icad Inc (ICAD, Financial) is $3.50 with a high estimate of $3.50 and a low estimate of $3.50. The average target implies an downside of 9.56% from the current price of $3.87. More detailed estimate data can be found on the icad Inc (ICAD) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, icad Inc's (ICAD, Financial) average brokerage recommendation is currently 2.8, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for icad Inc (ICAD, Financial) in one year is $1.63, suggesting a downside of 57.88% from the current price of $3.87. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the icad Inc (ICAD) Summary page.
